Oncology

Novartis sets out to debunk misconception that only smokers get lung cancer

Novartis sets out to debunk misconception that only smokers get lung cancer

By

Approximately 10% to 15% of lung cancer patients have never smoked and have developed the disease due to genetic alterations.

Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

By

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Five things for pharma marketers to know: Tuesday, August 16, 2016

Five things for pharma marketers to know: Tuesday, August 16, 2016

By

OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children

5 Ways to Improve the Customer Experience for Oncologists

5 Ways to Improve the Customer Experience for Oncologists

One critical aspect of oncology drugmakers' business remains firmly rooted in the past. That's customer experience.

One year on: Inside Bayer's effort to get prostate cancer patients to speak up

One year on: Inside Bayer's effort to get prostate cancer patients to speak up

By

Bayer recently tapped Ken Griffey Sr. and Ken Griffey Jr. — the first father-son duo to be inducted into the Baseball Hall of Fame — as spokespeople.

Five things for pharma marketers to know: Thursday, August 11, 2016

Five things for pharma marketers to know: Thursday, August 11, 2016

By

Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana

Opdivo bet backfires, creates opening for Merck to pursue DTC

Opdivo bet backfires, creates opening for Merck to pursue DTC

By

A massive disappointment for Bristol-Myers Squibb's Opdivo in first-line lung cancer has leveled the playfield for Merck's Keytruda.

Five things for pharma marketers to know: Monday, July 25, 2016

Five things for pharma marketers to know: Monday, July 25, 2016

By

Darzalex may interfere with blood testing; Kaine scrutinized for ties to pharma; medical societies are in support of bill exempting CME reporting

As immuno-oncology therapies evolve, so will the marketing

As immuno-oncology therapies evolve, so will the marketing

By

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Top 25 oncology products in 2015

Top 25 oncology products in 2015

Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.

CAR-T therapies: the future of cancer care, or an industry pipe dream?

CAR-T therapies: the future of cancer care, or an industry pipe dream?

By

While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

By

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Five things for pharma marketers to know: Monday, July 18, 2016

Five things for pharma marketers to know: Monday, July 18, 2016

By

Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages

Cancer detection tool among projects chosen for Publicis90 initiative

Cancer detection tool among projects chosen for Publicis90 initiative

By

U.S. companies accounted for nearly a quarter of the startups funded to celebrate Publicis' 90th anniversary.

Five things for pharma marketers to know: Wednesday, June 29, 2016

Five things for pharma marketers to know: Wednesday, June 29, 2016

By

GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center

Dudnyk's Angelina Sciolla on Refreshing the Oncology Narrative

Dudnyk's Angelina Sciolla on Refreshing the Oncology Narrative

Think chess game rather than bare knuckle brawl.

Five things for pharma marketers to know: Tuesday, June 21, 2016

Five things for pharma marketers to know: Tuesday, June 21, 2016

By

Cancer docs push HPV vaccine; GSK says experimental lung combo trumps Symbicort; Google rolls out new symptom search feature

Five things for pharma marketers to know: Friday, June 10, 2016

Five things for pharma marketers to know: Friday, June 10, 2016

By

FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec

Five things for pharma marketers to know: Wednesday, June 8, 2016

Five things for pharma marketers to know: Wednesday, June 8, 2016

By

Bing can identify people with cancer symptoms; an experimental rheumatoid arthritis meets trial goals; the FDA updates compassionate use rules

Bristol-Myers Squibb's Yervoy, Opdivo combo data confers edge in lung cancer

Bristol-Myers Squibb's Yervoy, Opdivo combo data confers edge in lung cancer

By

Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.

Five things for pharma marketers to know: Monday, June 6, 2016

Five things for pharma marketers to know: Monday, June 6, 2016

By

Researchers question cost of multiple-myeloma combo; drugmakers say CAR-T therapies will soon be approved; the FDA approves Allergan's hypertension drug

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.

Five things for pharma marketers to know: Friday, May 20, 2016

Five things for pharma marketers to know: Friday, May 20, 2016

By

Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices

Five things for pharma marketers to know: Wednesday, May 18, 2016

Five things for pharma marketers to know: Wednesday, May 18, 2016

By

Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year

Novartis splits pharma division, shakes up management team

Novartis splits pharma division, shakes up management team

By

Novartis breaks up pharmaceutical division and announces that David Epstein, CEO of Novartis Pharmaceuticals, will leave the company.

Novartis considers new sales model for experimental cancer therapy

Novartis considers new sales model for experimental cancer therapy

By

Using a med-tech strategy may help stem concern about CAR T-cell technology's complicated distribution and anticipated high prices, said Novartis exec.

Novartis launches DTC campaign for Entresto

Novartis launches DTC campaign for Entresto

By

The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

By

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

How Watson for Oncology is advancing cancer care

How Watson for Oncology is advancing cancer care

By

IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.

Rolling with the Punches as Marketing Evolves

Rolling with the Punches as Marketing Evolves

Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.

OPINION

Email Newsletters